ImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Copperwynd Financial LLC

Copperwynd Financial LLC grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 99.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,087 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Copperwynd Financial LLC’s holdings in ImmunityBio were worth $51,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of IBRX. GSA Capital Partners LLP lifted its position in shares of ImmunityBio by 290.3% during the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after acquiring an additional 80,318 shares during the period. Intech Investment Management LLC purchased a new position in shares of ImmunityBio during the 3rd quarter worth approximately $253,000. Charles Schwab Investment Management Inc. increased its stake in shares of ImmunityBio by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock worth $4,709,000 after purchasing an additional 29,665 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new position in shares of ImmunityBio during the 3rd quarter worth approximately $257,000. Finally, Quantbot Technologies LP purchased a new position in shares of ImmunityBio during the 3rd quarter worth approximately $143,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IBRX has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Thursday. Finally, D. Boral Capital reissued a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research note on Thursday. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ImmunityBio currently has an average rating of “Buy” and an average price target of $12.19.

ImmunityBio Stock Performance

IBRX stock opened at $2.87 on Friday. The stock has a market capitalization of $2.45 billion, a P/E ratio of -3.12 and a beta of 0.82. ImmunityBio, Inc. has a one year low of $2.28 and a one year high of $10.53. The company has a 50 day moving average price of $3.08 and a two-hundred day moving average price of $3.66.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. Research analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.